Blockchain

Dune Becomes the Most Comprehensive Onchain Data Hub for Polkadot’s 50+ Parachains

Boston, Mass, September 11th, 2024, Chainwire

 

New Integration Expands Dune’s Coverage Across the Entire Polkadot Ecosystem, Delivering Unmatched Onchain Analytics

Zurg, Switzerland, September 11th 2024 Dune, the leading platform for onchain analytics, announces the integration of 50+ parachains from the Polkadot ecosystem. With this expansion, Dune solidifies its position as the most comprehensive data hub for Polkadot, offering unparalleled insights and analytics for developers, investors, and data enthusiasts alike.

Earlier this year, Dune launched support for Polkadot, Kusama, and six parachains. Now, the platform takes a major step forward by expanding coverage to include the entire Polkadot ecosystem. This integration enables users to explore, analyze, and visualize all onchain activities across Polkadot in real time, making Dune the go-to destination for data-driven decision-making.

Polkadot’s ecosystem, known for its diverse and innovative parachains, generates a vast amount of data. Navigating this complex network can be a challenge. Dune’s expanded support simplifies access to crucial onchain data, empowering users to gain deeper insights into Polkadot’s dynamic ecosystem.

The newly integrated parachains include Moonbeam, which specializes in smart contracts and cross-chain DeFi; Acala, known as Polkadot’s hub for decentralized finance; Phala, which focuses on privacy-first DePIN and AI solutions; and Mythos, a protocol bringing AAA decentralized gaming and hugely popular franchises to Polkadot. These integrations, along with dozens of others, position Dune as the most expansive source for Polkadot’s onchain analytics, allowing users to track transaction flows, analyze DeFi activity, and monitor developments in gaming and NFTs—all within a single, comprehensive platform.

FredrikHaga, CEO of Dune shared, “Polkadot and its Substrate-based chains form a vast and complex ecosystem. With this integration of 50+ parachains, our goal is to make that complexity easier to navigate. We want to give people a clear, accessible view of what’s happening across the network, so they can focus on innovation and building with confidence.”

This milestone integration was achieved through Dune’s partnership with Colorful Notion. Together, the teams developed a streamlined process for integrating new parachains, ensuring Dune’s data remains comprehensive, accurate, and reliable.

Dune’s integration also includes enhanced functionality through the Dune API, allowing users to convert any query into a flexible API endpoint. This feature offers greater flexibility for developers and analysts, enabling them to seamlessly incorporate Dune’s data into their own applications.

To learn more about the latest Polkadot integrations, readers can visit Dune’s Polkadot Analytics.

About Dune 

Dune is a leading data analytics platform that democratizes access to onchain data by enabling users to query, visualize, and share insights across various blockchains. With over 700,000 community-contributed data tables, Dune supports comprehensive analysis of tokens, wallets, protocols, and more. The platform’s recent launch of the Dune API extends its capabilities for automated reporting, alerting, and integration into user applications.

For more information, readers can visit https://dune.com/home

About Polkadot

Polkadot is the powerful, secure core of Web3, providing a shared foundation that unites some of the world’s most transformative apps and blockchains. Polkadot offers advanced modular architecture that allows devs to easily design and build their own specialized blockchain projects, pooled security that ensures the same high standard for secure block production across all connected chains and apps connected to it, and robust governance that ensures a transparent system where everyone has say in shaping the blockchain ecosystem for growth and sustainability. With Polkadot, you’re not just a participant, you’re a co-creator with the power to shape its future.

 

Contact

Jonathan Duran
jonathan@distractive.xyz

PostAd_coinrule_banner728x90

Leave a Comment

Your email address will not be published. Required fields are marked *

*

PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics

2024-09-19T13:00:00Z

Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes

AMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven, multi-omic platform for early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions.

Prof. Mark Hoogendoorn, Co-CEO and Co-Founder PersonalAIze: "The strategic partnership between PersonalAIze and Cube has the potential to provide a transformative leap in healthcare diagnostics, uniting cutting-edge AI with trusted, high-performance capabilities and industry related in-depth expertise.”

Frank van Asch, Founder and CTO of RenovaroCube,” Together, we are pioneering a future where healthcare outcomes are improved by training models for multiple decisions through the entire health journey, ensuring the right accuracy for therapeutic decisions in every disease stage.”

The first phase of the collaboration focuses on establishing a strong foundation for the partnership, with PersonalAIze providing critical expertise in the integration of AI into healthcare. It will enhance existing collaborations with Academic and corporate partners and create new ones to build an eco-system to help develop and bring to the market a cutting-edge SaaS model and the next generation highly accurate diagnostics, starting with cancer.

Prof Sandjai Buhlai, Co-CEO and Co-Founder PersonalAIze: “This collaboration signals a bold step forward in utilizing the full potential of AI potentially to help revolutionize early-stage medical interventions and diagnosis at the earliest stage of cancer before imaging has been able to detect the tumors.”

Key contributions from PersonalAIze include:

  • Ethical AI: Ensuring the AI models are free from harmful biases and trained to support fairness and inclusivity in medical diagnostics.
  • Legal Guidance: Providing expert advice on legal responsibilities tied to AI outputs, including issues of AI accountability and potential liability.
  • Regulatory Compliance: Assisting in navigating existing and emerging regulations such as NEN, ISO, GDPR, and the AI Act, ensuring the platform adheres to all relevant healthcare regulations and clinical guidelines.
  • Medical and Diagnostic Input: Offering support in clinical validation in collaboration with medical scientists to ensure the AI is reliable and effective in real-world medical environments.
  • Explainable AI: Developing AI models that are transparent, fostering trust and confidence from both healthcare providers and patients.

Key Resources and Support from PersonalAIze
As part of the collaboration, PersonalAIze will contribute:

  • Expert Personnel: Including a Principal Investigator (PI) to lead clinical AI efforts, a project manager to coordinate the collaboration and a strategic advisor to oversee the scientific strategy and execution.
  • Research and Talent Capacity: Leveraging academic partnerships to ensure access to cutting-edge research and innovation and facilitating talent scouting to support the project’s development.
  • Academic Spin-Out Opportunities: Supporting the commercialization of academic research through potential spin-out ventures related to AI diagnostics.
  • Co-Development of AI Platform: Jointly developing a science-driven, evidence-based AI platform that meets rigorous clinical and regulatory standards.
  • Ongoing Research and Publications: Contributing to the body of research through support with peer-reviewed publications in collaboration with clinical experts that will help build trust within the medical community and among regulatory bodies.
  • Architecture and Strategy Guidance: Continuously advising on the platform’s architecture and strategic direction, ensuring it stays aligned with the latest industry trends and scientific advancements.
  • Trusted AI: Developing a trustworthy, explainable AI platform that inspires confidence among healthcare providers and patients through clear and transparent decision-making processes.

About PersonalAIze
PersonalAIze focuses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision-making systems as well as improvement of health care operations such as capacity planning.

About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.

Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.


GlobeNewsWire News

Recent Comments